Expression and purification of the aortic amyloid polypeptide medin  by Davies, Hannah A. et al.
Protein Expression and Puriﬁcation 98 (2014) 32–37Contents lists available at ScienceDirect
Protein Expression and Puriﬁcation
journal homepage: www.elsevier .com/ locate /yprepExpression and puriﬁcation of the aortic amyloid polypeptide medinhttp://dx.doi.org/10.1016/j.pep.2014.02.009
1046-5928/ 2014 Published by Elsevier Inc.
⇑ Corresponding author. Tel.: +44 1524 594328.
E-mail address: d.middleton@lancaster.ac.uk (D.A. Middleton).
1 Abbreviations used: SSNMR, solid-state nuclear magnetic resonance; AMA, aortic
medial amyloid; IMAC, immobilised metal afﬁnity chromatography; DAB, diam-
inobenzidine tetrahydrochloride; TEM, transmission electron microscopy; TEV,
tobacco etch virus; DLS, dynamic light scattering.Hannah A. Davies a, Mark C. Wilkinson a, Robert P. Gibson a, David A. Middleton b,⇑
a Institute of Integrative Biology, Biosciences Building, Crown Street, University of Liverpool, Liverpool L69 7ZB, United Kingdom
bDepartment of Chemistry, Lancaster University, Lancaster LA1 4YB, United Kingdoma r t i c l e i n f o
Article history:
Received 6 December 2013
and in revised form 12 February 2014
Available online 3 March 2014
Keywords:
Amyloid
Fibril
SUMO
pOPINS
Solid-state NMRa b s t r a c t
The 50-amino acid protein medin is the main ﬁbrillar component of human aortic medial amyloid (AMA),
the most common form of localised amyloid which affects 97% of Caucasians over the age of 50. Struc-
tural models for several amyloid assemblies, including the Alzheimer’s amyloid-b peptides, have been
deﬁned from solid-state nuclear magnetic resonance (SSNMR) measurements on 13C- and 15N-labelled
protein ﬁbrils. SSNMR-derived structural information on ﬁbrillar medin is scant, however, because
studies to date have been restricted to limited measurements on site-speciﬁcally labelled protein
prepared by solid-phase synthesis. Here we report a procedure for the expression of a SUMO-medin
fusion protein in Escherichia coli and IMAC puriﬁcation yielding pure, uniformly 13C,15N-labelled medin
in quantities required for SSNMR analysis. Thioﬂavin T ﬂuorescence and dynamic light scattering
measurements and transmission electron microscopy analysis conﬁrm that recombinant medin assem-
bles into amyloid-like ﬁbrils over a 48-h period. The ﬁrst 13C and 15N SSNMR spectra obtained for
uniformly-labelled ﬁbrils indicate that medin adopts a predominantly b-sheet conformation with some
unstructured elements, and provide the basis for further, more detailed structural investigations.
 2014 Published by Elsevier Inc.Introduction
Over 30 proteins and peptides polymerise via soluble oligo-
meric intermediates into insoluble amyloid or amyloid-like ﬁbrils
associated histopathologically with human disorders including
Alzheimer’s, Parkinson’s and type II diabetes [1,2]. Despite consid-
erable research into the cellular and molecular basis of amyloidos-
es, there is no clear consensus as to the contribution of amyloid to
disease or how amyloid pathogenicity is inﬂuenced by the struc-
ture of the protein assemblies at the molecular level. There is sub-
stantial evidence that the pre-ﬁbrillar aggregates of amyloidogenic
proteins and peptides are cytotoxic [3–7], and the mature ﬁbrillar
deposits detected in tissue by immunochemical staining may con-
sequently be a benign end-point of the assembly process [8,9]. Fur-
ther research is required to elucidate the nature and cytotoxic
mechanism of these species at the molecular level in order to guide
the development of targeted therapies. Solid-state nuclear
magnetic resonance (SSNMR)1 of 13C- and 15N-labelled protein
ﬁbrils has played a valuable role in these ongoing research effortsand has been utilised to deﬁne structural models for several amyloid
assemblies, including the Alzheimer’s amyloid-b peptides, the hu-
man islet amyloid polypeptide and b2-microglobulin [10–16].
Aortic medial amyloid (AMA) is the most common form of local-
ised amyloid identiﬁed to date, affecting 97% of Caucasians over
the age of 50 [17]. It occurs predominately in the medial layer of
the aorta and may have a role in vascular pathologies such as tho-
racic aneurysm and dissection [18]. The major protein component
of AMA is ﬁbrillar medin (AMed), a cleavage product of the glyco-
protein lactadherin [19]. AMed was ﬁrst isolated from cadaveric
tissue of three patients with extensive medial amyloid deposits,
the isolated proteins had a ragged N-terminus but the main protein
component consisted of the 50 amino acid polypeptide medin
(Fig. 1A) [17,19]. The 8 C-terminal residues of medin are important
for aggregation [20] and a peptide corresponding to residues 42–49
(Med42–49) forms needle-like aggregates composed of parallel
hydrogen-bonded b-strands aligned in-register [11]. SSNMR analy-
sis of selectively 13C-labelled medin and Med42–49 ﬁbrils prepared
by solid-phase synthesis indicates differences in the packing
arrangements of the C-terminal amino acid side-chains (7). Very
little else is known about the molecular architecture of medin
ﬁbrils, however, and a more detailed structural analysis of
full-length medin using SSNMR will require extensively or uni-
formly 13C and 15N labelled protein. To date, however, no detailed
procedure has been published for the production of medin in
Fig. 1. Amino acid sequence of medin (A) and schematic of pOPINS construct, black arrow indicates SUMO protease cleavage site (B).
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initially employed a pMal vector construct commonly used for
expression in Escherichia coli of amyloidogenic peptides fused with
maltose binding protein, but this approach was aborted because of
difﬁculties encountered with the proteolytic cleavage of medin
after puriﬁcation by afﬁnity chromatography. We report here that
the successful expression and puriﬁcation of medin is achieved
using a pOPINS vector to express the protein fused with an N-
His6-SUMO tag. The Alzheimer’s Ab1–42 polypeptide was previously
expressed and puriﬁed with a SUMO tag [21], but the utility of this
approach for the production of other amyloidogenic proteins has
until now not been demonstrated. The preparative procedure de-
scribed yielded up to 6 mg of ﬁbrillar protein per litre of growth
media. We present the ﬁrst 13C and 15N SSNMR spectra of
uniformly 13C 15N-labelled medin ﬁbrils. This protocol will allow
further characterisation of medin using SSNMR and other biophys-
ical techniques.Materials and methods
Vector and cloning
Initially the medin gene was prepared synthetically and in-
serted into a pMalC2X vector by GenScript (U.S.A.). In order to im-
prove the yield and facilitate puriﬁcation of the target protein, the
medin gene was sub-cloned into pOPINS vector using the In-
Fusion™ method [22]. The pOPIN suite of vectors developed at
the Oxford Protein Production Facility can be used in conjunction
with the In-Fusion™ PCR cloning system (Clontech) [22]. This
method is a ligase independent method that is quicker and more
efﬁcient than many sub-cloning techniques and the pOPIN suite
provides several options for fusion partners and cleavage sites.
The pOPINS vector is derived from the pET 28a vector and com-
prises a N-His6-SUMO tag with kanamycin resistance (Fig. 1B).
The resultant vector was sequenced to conﬁrm the insertion of
medin (GATC).Expression of medin
The pOPINS-medin plasmid was transformed into E. coli BL21
(DE3) competent cells (Top 10, NEB). For expression of unlabelled
medin a colony was then selected and grown in 50 ml of Luria
Broth (LB) containing kanamycin at a concentration of 35 lg/ml
overnight at 37 C. This culture was then harvested by centrifuga-
tion at 3000g and used to inoculate 2 L of LB. The culture was
incubated at 37 C until an O.D.600 = 0.8–1 was reached. Expression
of the fusion protein was induced by the addition of isopropyl b-D-
thiogalactoside (IPTG) to a ﬁnal concentration of 1 mM and the cell
growth allowed to continue for a further 16 h at 20 C. Cells were
harvested by centrifugation at 3000g for 20 min at 4 C. This pro-
cess generated on average a 12 g/L of wet cell pellet in LB and 9 g/L
in minimal media. Cell pellets were resuspended in 40 ml of buffer
A (20 mM Tris, 0.5 M NaCl, pH. 7.4) and frozen at 20 C in prepa-
ration for lysis and puriﬁcation.
Expression of 15N/13C labelled medin proceeded as described
above except that the 50 ml overnight starter culture grown inLB was resuspended in 2 L of M9 minimal medium containing 2 g
of 15NH4Cl and 8 g of 13C-glucose.
Cell lysis and puriﬁcation
The SUMO-medin fusion (18,163 Da) protein can be isolated
from crude extract with the use of afﬁnity chromatography. The
presence of the His6-tag enables the use of immobilised metal
afﬁnity chromatography (IMAC), using resin functionalised with
Ni2+ ions. The bound protein is then eluted with imidazole, which
competes with the histidines to chelate the Ni2+.
The resuspended cells (from 1 L of culture) in 40 ml buffer A
were subjected to a single freeze–thaw cycle prior to 2 French
press cycles in the presence of DNase at a ﬁnal concentration of
20 ng/ml and a cOmplete EDTA-free™ protease inhibitor cocktail
tablet (Roche Applied Sciences). The lysed cells were then
centrifuged at 19,000g to remove the cell debris and the superna-
tant ﬁltered through a 0.22 lm AcrodiscTM ﬁlter. A 5 ml His-Trap
FF ™ column (GE Healthcare) was equilibrated with 5 column vol-
umes (CV) of buffer A and 5 CV of buffer B (20 mM Tris, 0.5 M NaCl,
0.5 M imidazole) followed by a further 5 CV of buffer A at 4 ml/min
and the supernatant loaded using an AKTA puriﬁcation system at
1 ml/min (GE Healthcare). The fusion protein was eluted from
the column with a step-wise gradient, with the target protein
eluting at 0.2 M imidazole concentration. The fusion protein was
collected and desalted using a 26/10 desalting column (GE Health-
care) to remove the imidazole.
Tag removal
The His6-SUMO tag was removed by incubation with SUMO
protease I at 30 C for 2 h as per the manufacturer’s instructions
(Tebu-bio) to yield the cleaved tag (12,372 Da) and medin
(5430 Da). Following cleavage, a second IMAC puriﬁcation step
was performed to remove the cleaved His6-SUMO tag and the
His6-SUMO protease. The cleavage mixture was passed through a
5 ml Ni2+ NTA column and the ﬂow through containing medin col-
lected. Medin was collected in the ﬂow-through and prepared for
aggregation and NMR studies.
Gel electrophoresis
The expression and puriﬁcation of medin was analysed by SDS–
PAGE using the Laemmli method [23]. Analysis was carried out
using 15% Tris-Tricine gels [24] in a Bio-Rad gel electrophoresis
system. 5 ll protein samples were added to 5 ll of 2 sample buf-
fer, boiled for 5 min and loaded onto the gel. All gels were run at
200 V for 60 min, stained with Coomassie brilliant blue G-250
and de-stained with H2O, methanol, and acetic acid in a ratio of
50/40/10 (v/v/v).
Western blot analysis
Polyclonal antibodies against two epitopes of medin,
corresponding to residues 1–10 and 19–31, were raised in rabbit
and puriﬁed by GenicBio (Hong Kong). Anti-rabbit IgG horseradish
Table 1
Comparison of medin puriﬁcation yields per litre between rich media (LB) and
minimal media (MM) determined using absorbance at 280 nm. The estimated amount
of medin within fusion protein is shown in parentheses.
Puriﬁcation step Yield in LB (mg) Yield in MM (mg)
Captured fusion proteina 25 (7.5) 18 (5.4)
Desalting 24 (7.2) 17 (5.2)
IMAC removal of His tag 6 3
a The yield of fusion protein obtained following IMAC puriﬁcation.
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Tris-Tricine 15% gels were run as described above and then trans-
ferred to PVDF membrane for 30 min at 100 V. Then membrane
was blocked overnight at room temperature with PBS + 5 mg/ml
BSA prior to addition of the primary antibody in blocking buf-
fer + 0.5% Tween. Following a 1 h incubation at room temperature,
the membrane was washed and then incubated with anti-rabbit
IgG peroxidase conjugate (A6154). The immunoreactive bands
were visualised with 0.5 mg/ml 3,30-diaminobenzidine tetrahydro-
chloride (DAB) (Sigma Aldrich) and H2O2 (0.015% v/v) in PBS.
Tryptic digest
Puriﬁed peptide (2 lg) was resuspended in 50 mM ammonium
bicarbonate pH 7.8 containing 2 M urea and digested overnight
with 0.1 lg trypsin. The resulting peptides were cleaned up using
C18 Zip Tips (Millipore) in readiness for analysis by either
MALDI-MS or ES-MS. MALDI-MS analysis was performed using a
MALDI-TOF instrument (Waters-Micromass) on samples dried
onto the target plate using a saturated solution of alpha-cyano-4
hydroxycinnaminic acid in 50% acetonitrile/0.1% triﬂuoroacetic
acid. For ES-MS analysis, the sample was infused into the nano
electrospray source of the mass spectrometer (Waters Q-ToF
micro), at a ﬂow rate of 150 ll/h, via a gas tight syringe. The posi-
tive ion mass spectrum of the sample was recorded.
Sample preparation for biophysical analysis
Medin was concentrated in an centrifugal ﬁlter device (Merck-
Millipore, 3 KDa MW cut-off) and dialysed into aggregation buffer
(20 mM Tris, 150 mM NaCl, pH.7.4) using a 0.5 ml Slide-a-Lyzer
(Fisher Scientiﬁc) with a 3.5 KDa MW cut-off.
Thioﬂavin T
Thioﬂavin T (ThT) assays were carried out on a Flexstation 3
microplate reader (Molecular Devices Ltd). Experiments were car-
ried out in 96-well black-walled, clear bottomed microplates
(Nunc) with data recorded using bottom read mode. ThT solution
was injected into the protein samples (20 lM peptide in 20 mM
NaPhos, 150 mM NaCl pH 7.4) at the start of the read, to a ﬁnal
ThT concentration of 20 lM. The wells were mixed with two cycles
of trituration prior to recording data. Fluorescent measurements,
representing the average of 6 ﬂashes, were recorded every 5 min
throughout the duration of the experiments, with the photomulti-
plier tube sensitivity set to medium. The dye was excited at
450 nm and the emission signal recorded at 485 nm with a cut-
off of 475 nm. Each data set was conducted in triplicate and the
average plotted as a function of time.
Dynamic light scattering
DLS measurements were carried out on a Zetasizer nano instru-
ment (Malvern instruments) on both freshly prepared and aggre-
gated 20 lM medin samples in aggregation buffer. Each
experiment was carried out in a 3 mm quartz cuvette at 25 C
and results are presented as average values from 15 scans.
Electron microscopy
The morphology of the medin aggregates were analysed using
transmission electron microscopy (TEM). 10 ll of ﬁbril solution
was loaded onto carbon coated copper grids and stained with 4%
uranyl acetate. The grids were visualised on a Tecnai 10 electron
microscope operating at 100 kV.Solid state NMR
Uniformly 13C- and 15N-labelled recombinant medin was con-
centrated to 200 lM and agitated at 25 C for 14 days to form ﬁ-
brils. One-dimensional 13C and 15N cross-polarisation magic-
angle spinning spectra were obtained on a Bruker 850 MHz
wide-bore solid-state NMR spectrometer. The experimental condi-
tions were: 14 kHz sample rotation, 1-ms Hartmann–Hahn contact
time, 100 kHz proton decoupling and a 1.5-s recycle delay.Results
MBP as a possible fusion partner
Initially maltose binding protein was selected as a fusion
partner for recombinant medin expression as it has been used pre-
viously to improve solubility of amyloid proteins such as a-synuc-
lein [25], Ab [26] and amylin [27]. A synthetically produced medin
gene was inserted into the pMALC2X vector by Genscript (U.S.A.).
The pMALC2X vector was modiﬁed to include a tobacco etch virus
(TEV) protease cleavage site between the MBP and medin se-
quences. This construct gave a good yield of soluble fusion protein
however the cleavage of the fusion protein was inefﬁcient and de-
spite optimisation attempts could not be signiﬁcantly improved
and resulted in very poor overall yield (<1 mg/L of rich culture)
unsuitable for structural analyses (data not presented). It was
therefore decide to explore alternative fusion partners and cleav-
age mechanisms.Expression and puriﬁcation of His6-SUMO-medin fusion protein
The pOPINS vector was chosen as an alternative construct for
medin expression. It encodes the fusion partner His6-SUMO which
is highly soluble and can therefore reduce incorporation of this
highly amyloidogenic peptide into inclusion bodies [28]. This con-
struct gave rise to a high level of over expression in the soluble
fraction (approximately 90%). Furthermore the addition of a His6
tag allowed for IMAC puriﬁcation, which reduced the number of
puriﬁcation steps required and resulted in relatively high purity
at capture stage (Fig. 1B). SDS–PAGE gel analysis of the Ni2+ column
ﬂow through did not indicate the presence of any fusion protein
suggesting close to 100% capture. Importantly, the fusion protein
can be cleaved using SUMO protease, which recognises the tertiary
structure of the SUMO tag opposed to the sequential recognition of
TEV and many other proteases. This resulted in 100% cleavage of
the fusion protein and a greatly improved overall yield. Approxi-
mately 6 mg and 3 mg of unlabelled and isotopically labelled med-
in were obtained from 1 L of culture, respectively (Table 1).
To our knowledge, only one earlier example of the use of SUMO
for the expression of full length amyloid proteins has been re-
ported in the literature [21], and none using the pOPINS vector
construct. The improvement observed here support the previous
ﬁndings that suggest that SUMO may be a preferable system for
Fig. 2. SDS PAGE of puriﬁed medin (A), Lane 1. Puriﬁed medin. Lane 2. Low
molecular weight markers (Sigma). Western blot analysis of medin (B). Lane 1. See
Blue Pre-Stained Standard (Invitrogen), Lane 2. Medin. Visualised using 3,30-
diaminobenzidine tetrahydrochloride (DAB). Arrows indicate monomeric medin.
The second band may indicate the presence of a medin tetramer at 21.7 KDa.
Table 2
Comparison of tryptic digest expected masses obtained from PeptideMass server
(ExPASy) and experimentally determined masses from both MALDI and ES-MS.
Fragment sequence Expected mass MALDI ES-MS
R – – –
LDK – – –
QGNFNAWVAGSYGNDQWLQVDLGSSK 2841.3 2841.2
EVTGIITQGAR 1144.6 1144.5 1144.5
NFGSVQFVA 968.4
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structural studies.Conﬁrmation of medin
Western blot analysis conﬁrmed the presence of the medin
sequence (Fig. 2B). The western blot indicates the presence of
monomeric medin (indicated by arrow, Fig. 2B) and a possible
aggregated tetrameric form of medin (21.7 KDa). The puriﬁcation
product was subject to trypic digest and subsequent mass
spectrometry analysis. Three of the four expected fragments were
identiﬁed covering 80% of the sequence (Table 2). The C-terminalFig. 3. Medin ﬁbril formation. (A) The effect of protein concentration upon medin aggre
spectrometer at 30 C under quiescent conditions. Data represent mean ﬂuorescence i
aggregation buffer) at 0 and 48 h. Data recorded using a Zetasizer nano instrument operat
electron microscopy images of medin ﬁbrils formed under quiescent conditions, at 30 Cfragment NFGSVQFVA was not observed, but, because this region
is a highly amyloidogenic part of the peptide [11,29], it is possible
that rapid aggregation and precipitation occurs when cleaved from
the rest of the peptide and thus the fragment is invisible by mass
spectrometry.
Aggregation properties of medin
The aggregation kinetics of recombinant medin under quiescent
conditions were analysed using Thioﬂavin T ﬂuorescence. An
increase in ﬂuorescence intensity is associated with levels of the
characteristic cross-b structure of amyloid ﬁbrils. The data shown
in Fig. 3A indicate that medin aggregation occurs over a period of
48 h via nucleation dependent growth with the characteristic lag
phase, followed by an exponential growth and elongation phase.
Dynamic light scattering (DLS) provides information about the
size distribution of particles in solution. DLS was used here to
monitor changes in the distribution of medin particles over the
time-course of aggregation. As can be seen in Fig. 3B, the initial
particle size in a freshly prepared medin solution is consistent with
monomeric peptide species in a compact conformation, whereas
after 48 h much larger higher aggregates have formed. These data
indicate, like the ThT, that aggregation occurs within 48 h.
The morphology of the resultant aggregates was analysed by
transmission electron microscopy. Images show slender,
unbranched ﬁbrillar aggregates with an approximate diameter of
10 nm, consistent with other amyloid assemblies (Fig. 3C) [30].
Solid-state NMR analysis of medin ﬁbrils
Proton decoupled 13C and 15N spectra were collected for full
length recombinant medin (Fig. 4). The spectra show that medin
was successfully isotopically labelled with both 13C and 15N. In
both spectra the resonance lines were rather broader than has been
observed for Ab1–40, for example, [31,32], consistent either with
structural heterogeneity of medin within the ﬁbrils or different
morphological ﬁbril forms, or both. It may be possible to obtain
morphologically-pure strains of medin ﬁbrils by employing several
iterations of ﬁbril seeding [33,34], to provide NMR spectra with
narrower line widths suitable for detailed structural analysis. The
procedure reported here nevertheless yielded isotopically-labelled
medin ﬁbrils that enabled us to obtain the ﬁrst structural informa-
tion using solid-state NMR. The 13C and 15N spectra were compared
with simulated spectra generated with reference to the chemical
shift values predicted for medin modelled in 100% a-helical or b-
sheet conformations, or as a random coil (Fig. 5). In the backbonegation measured by thioﬂavin T ﬂuorescence. Data were recorded on a ﬂuoromax
ntensities for 3 replicates. (B) Dynamic light scattering data for medin (20 lM in
ing at 25 C; data shows an increase in particle size over time. (C) Negatively stained
, at a medin concentration of 20 lM in aggregation buffer.
Fig. 4. Solid state MAS NMR spectra of uniformly 13C and 15N labelled medin ﬁbrils.
(A) Proton decoupled 15N spectrum obtained after 20,480 scans. (B) Proton
decoupled 13C spectrum obtained after 1024 scans.
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frequencies is consistent with simulated spectra for medin in a
partial b-sheet structure with additional contributions from
a-helical and/or random coil elements (which largely overlap with
each other) (Fig. 5A). The regions of the 13C spectra that are most
sensitive to secondary structure (i.e., in the frequency range of
the a-, b- and backbone amide carbons) correspond closely with
the simulated spectrum for medin b-sheets Fig. 5B, top), and to a
lesser extent with the simulated spectrum for medin as a random
coil (data not presented). By contrast, the simulated spectrum for a
medin a-helix is in much poorer agreement with the data (Fig. 5B,
bottom). Hence the 15N and 13C spectra indicate that ﬁbrillar medin
is predominantly b-sheet with some unstructured elements, with
little or no a-helical content. These preliminary results lay the
foundations for further structural analysis using multidimensional
solid-state NMR methods.Fig. 5. Comparison of experimental spectra and simulated spectra. (A) Experimen-
tal 15N spectrum superimposed with a simulated spectrum for a medin b-sheet (left,
dashed line) and with simulated spectra for an a-helix (right, dashed line) and
random coil (right, bold solid line). (B) Experimental 13C spectrum superimposed
with a simulated spectrum for a b-sheet (top, dashed line) and a-helix (bottom,
dashed line). Simulated spectra were generated by a computer programme written
speciﬁcally for that purpose, using chemical shifts for each residue as predicted by
ShiftX2 [35] from PDB ﬁles for medin modelled as 100% b-sheet or a-helix, or using
random coil shifts taken from [36].Discussion
Aortic medial amyloid is the most common form of localised
amyloid yet there remains no published method for the large scale
expression and puriﬁcation of medin. Chemically synthesised
proteins are expensive to purchase and often difﬁcult to obtain
therefore it is preferable to use an expression host which is more
cost-effective and provides a replenishable source of peptide.
Furthermore, there is evidence that synthetically produced and
recombinant proteins behave differently in vitro [28]. The lack of
a reliable expression protocol has limited research on medin and
AMA. The objective of this work was to establish expression and
puriﬁcation protocols for the production of recombinant medin
for future characterisation studies. Moreover, the use of an E. coliexpression host enables the relatively facile incorporation of iso-
tope labels required for NMR structural analysis.
Medin was ultimately cloned into the pOPINS vector and ex-
pressed in BL21 (DE3) E. coli cells. Small proteins are often suscep-
tible to proteolytic degradation; the use of a fusion protein can
help protect the peptide from degradation. The use of afﬁnity or
solubility tags can also assist in the puriﬁcation. The pOPINS vector
H.A. Davies et al. / Protein Expression and Puriﬁcation 98 (2014) 32–37 37contains both a His6 afﬁnity tag and a SUMO solubility tag and
these tags improved the expression and puriﬁcation of medin.
This work also demonstrates for the ﬁrst time the expression of
uniform 13C/15N isotopically labelled medin suitable for NMR
structural studies. Expression in minimal media produced 3 mg
of uniform 13C/15N isotopically labelled medin per litre of culture.
These protocols will now enable in depth studies into the biophys-
ical and structural properties of medin and could lead to a greater
understanding of how this polypeptide affects the physiology of
the aorta and other blood vessels.Acknowledgments
We thank Dr. Jillian Madine for technical assistance and for help
in the preparation of this manuscript. Financial support for this
work (PhD studentship to HAD) was provided by the British Heart
Foundation (Grant Number FS/09/033/27742). The UK 850 MHz
solid-state NMR Facility used in this research was funded by EPSRC
and BBSRC, as well as the University of Warwick including via part
funding through Birmingham Science City Advanced Materials Pro-
jects 1 and 2 supported by Advantage West Midlands (AWM) and
the European Regional Development Fund (ERDF).References
[1] C.M. Dobson, Protein aggregation and its consequences for human disease,
Protein Pept. Lett. 13 (2006) 219–227.
[2] D.J. Selkoe, Cell biology of protein misfolding: the examples of Alzheimer’s and
Parkinson’s diseases, Nat. Cell Biol. 6 (2004) 1054–1061.
[3] M. Stefani, Structural features and cytotoxicity of amyloid oligomers:
implications in Alzheimer’s disease and other diseases with amyloid
deposits, Prog. Neurobiol. 99 (2012) 226–245.
[4] J.C. Stroud, C. Liu, P.K. Teng, D. Eisenberg, Toxic ﬁbrillar oligomers of amyloid-b
have cross-b structure, Proc. Natl. Acad. Sci. 109 (2012) 7717–7722.
[5] A.L. Gharibyan, V. Zamotin, K. Yanamandra, O.S. Moskaleva, B.A. Margulis, I.A.
Kostanyan, L.A. Morozova-Roche, Lysozyme amyloid oligomers and ﬁbrils
induce cellular death via different apoptotic/necrotic pathways, J. Mol. Biol.
365 (2007) 1337–1349.
[6] H.-J. Kim, S.-C. Chae, D.-K. Lee, B. Chromy, S.C. Lee, Y.-C. Park, W.L. Klein, G.A.
Krafft, S.-T. Hong, Selective neuronal degeneration induced by soluble
oligomeric amyloid beta protein, FASEB J. 17 (2003) 118–120.
[7] R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, C.G.
Glabe, Common structure of soluble amyloid oligomers implies common
mechanism of pathogenesis, Science 300 (2003) 486–489.
[8] M.E. Larson, S.E. Lesne, Soluble Abeta oligomer production and toxicity, J.
Neurochem. 120 (Suppl. 1) (2012) 125–139.
[9] J. Gotz, A. Eckert, M. Matamales, L.M. Ittner, X. Liu, Modes of A beta toxicity in
Alzheimer’s disease, Cell. Mol. Life Sci. 68 (2011) 3359–3375.
[10] H.A. Davies, J. Madine, D.A. Middleton, Solid-state NMR reveals differences in
the packing arrangements of peptide aggregates derived from the aortic
amyloid polypeptide medin, J. Pept. Sci. 18 (2012) 65–72.
[11] J. Madine, A. Copland, L.C. Serpell, D.A. Middleton, Cross-b spine architecture of
ﬁbrils formed by the amyloidogenic segment NFGSVQFV of medin from solid-
state NMR and X-ray ﬁber diffraction measurements, Biochemistry 48 (2009)
3089–3099.
[12] J. Madine, A.J. Doig, D.A. Middleton, Design of an N-methylated peptide
inhibitor of a-synuclein aggregation guided by solid-state NMR, J. Am. Chem.
Soc. 130 (2008) 7873–7881.
[13] H. Amijee, J. Madine, D.A. Middleton, A.J. Doig, Inhibitors of protein
aggregation and toxicity, Biochem. Soc. Trans. 37 (2009) 692–696.[14] R. Tycko, Applications of solid state NMR to the structural characterization of
amyloid ﬁbrils: methods and results, Prog. Nucl. Magn. Reson. Spectrosc. 42
(2003) 53–68.
[15] R. Tycko, Characterization of amyloid structures at the molecular level by solid
state nuclear magnetic resonance spectroscopy, Methods Enzymol. 413 (2006)
103–122.
[16] H. Heise, Solid-state NMR spectroscopy of amyloid proteins, Chembiochem 9
(2008) 179–189.
[17] G.T. Westermark, P. Westermark, Localized amyloids important in diseases
outside the brain – lessons from the islets of Langerhans and the thoracic
aorta, FEBS J. 278 (2011) 3918–3929.
[18] S. Peng, A. Larsson, E. Wassberg, P. Gerwins, S. Thelin, X. Fu, P. Westermark,
Role of aggregated medin in the pathogenesis of thoracic aortic aneurysm and
dissection, Lab. Invest. 87 (2007) 1195–1205.
[19] B. Häggqvist, J. Näslund, K. Sletten, G.T. Westermark, G. Mucchiano, L.O.
Tjernberg, C. Nordstedt, U. Engström, P. Westermark, Medin: an integral
fragment of aortic smooth muscle cell-produced lactadherin forms the most
common human amyloid, Proc. Natl. Acad. Sci. 96 (1999) 8669–8674.
[20] A. Larsson, L. Söderberg, G.T. Westermark, K. Sletten, U. Engström, L.O.
Tjernberg, J. Näslund, P. Westermark, Unwinding ﬁbril formation of medin, the
peptide of the most common form of human amyloid, Biochem. Biophys. Res.
Commun. 361 (2007) 822–828.
[21] M. Satakarni, R. Curtis, Production of recombinant peptides as fusions with
SUMO, Protein Expr. Purif. 78 (2011) 113–119.
[22] N.S. Berrow, D. Alderton, S. Sainsbury, J. Nettleship, R. Assenberg, N. Rahman,
D.I. Stuart, R.J. Owens, A versatile ligation-independent cloning method
suitable for high-throughput expression screening applications, Nucleic
Acids Res. 35 (2007).
[23] U.K. Laemmli, Cleavage of structural proteins during the assembly of the head
of bacteriophage T4, Nature 227 (1970) 680–685.
[24] H. Schägger, G. von Jagow, Tricine-sodium dodecyl sulfate-polyacrylamide gel
electrophoresis for the separation of proteins in the range from 1 to 100 kDa,
Anal. Biochem. 166 (1987) 368–379.
[25] M. Zhao, D. Cascio, M.R. Sawaya, D. Eisenberg, Structures of segments of a-
synuclein fused to maltose-binding protein suggest intermediate states during
amyloid formation, Protein Sci. 20 (2011) 996–1004.
[26] J. Caine, I. Volitakis, R. Cherny, J. Varghese, I. Macreadie, A beta produced as a
fusion to maltose binding protein can be readily puriﬁed and stably associates
with copper and zinc, Protein Pept. Lett. 14 (2007) 83–86.
[27] J.J.W. Wiltzius, S.A. Sievers, M.R. Sawaya, D. Eisenberg, Atomic structures of
IAPP (amylin) fusions suggest a mechanism for ﬁbrillation and the role of
insulin in the process, Protein Sci. 18 (2009) 1521–1530.
[28] V.H. Finder, I. Vodopivec, R.M. Nitsch, R. Glockshuber, The recombinant
amyloid-beta peptide A beta 1–42 aggregates faster and is more neurotoxic
than synthetic A beta 1–42, J. Mol. Biol. 396 (2010) 9–18.
[29] M. Reches, E. Gazit, Amyloidogenic hexapeptide fragment of medin: homology
to functional islet amyloid polypeptide fragments, Amyloid 11 (2004) 81–89.
[30] M. Sunde, L.C. Serpell, M. Bartlam, P.E. Fraser, M.B. Pepys, C.C.F. Blake, Common
core structure of amyloid ﬁbrils by synchrotron X-ray diffraction, J. Mol. Biol.
273 (1997) 729–739.
[31] J. Madine, M.J. Pandya, M.R. Hicks, A. Rodger, E.A. Yates, S.E. Radford, D.A.
Middleton, Site-speciﬁc identiﬁcation of an Ab ﬁbril–heparin interaction site
by using solid-state NMR spectroscopy, Angew. Chem. 51 (2012) 13140–
13143.
[32] A.T. Petkova, Y. Ishii, J.J. Balbach, O.N. Antzutkin, R.D. Leapman, F. Delaglio, R.
Tycko, A structural model for Alzheimer’s b-amyloid ﬁbrils based on
experimental constraints from solid state NMR, Proc. Natl. Acad. Sci. U.S.A.
99 (2002) 16742–16747.
[33] A.T. Petkova, R.D. Leapman, Z.H. Guo, W.M. Yau, M.P. Mattson, R. Tycko, Self-
propagating, molecular-level polymorphism in Alzheimer’s beta-amyloid
ﬁbrils, Science 307 (2005) 262–265.
[34] A.K. Paravastu, I. Qahwash, R.D. Leapman, S.C. Meredith, R. Tycko, Seeded
growth of b-amyloid ﬁbrils from Alzheimer’s brain-derived ﬁbrils produces a
distinct ﬁbril structure, Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 7443–7448.
[35] B. Han, Y. Liu, S. Ginzinger, D. Wishart, SHIFTX2: signiﬁcantly improved
protein chemical shift prediction, J. Biomol. NMR 50 (2011) 43–57.
[36] Y. Wang, O. Jardetzky, Probability-based protein secondary structure
identiﬁcation using combined NMR chemical-shift data, Protein Sci. 11
(2002) 852–861.
